Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492400 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 363
- Enrollment target
NCT01492400 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 363 participants.
The verdict
NCT01492400, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 363 participants
- Enrollment target
Study Summary
This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).
Interventions
- DRUG ranibizumab
- DRUG dexamethasone Intravitreal Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2012-03-09 |
| Est. Completion | 2014-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01492400
The ClinicalTrials.gov registry entry for NCT01492400 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ranibizumab is the first listed.
NCT01492400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01492400 about?
NCT01492400 is a clinical study titled "Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema". This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).
What is the current status of trial NCT01492400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 363 participants. The study started on 2012-03-09. Estimated completion is 2014-02-13.
What interventions are being tested in trial NCT01492400?
The interventions under investigation include: ranibizumab (DRUG), dexamethasone Intravitreal Implant (DRUG).
Who is sponsoring clinical trial NCT01492400?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.